PERSEUS
Adding daratumumab to the standard three-drug induction and to maintenance cut the risk of progression by more than half in transplant-eligible myeloma.
48-month PFS 84.3% vs 67.7% (HR 0.42); MRD negativity (10⁻⁵) 75% vs 48%; sustained MRD-negativity ≥12 months 64.8% vs 29.7%. Approved July 2024. Dara discontinued after sustained MRD negativity in the experimental arm (MRD-guided de-escalation embedded).
- 84.3 vs 67.7 out of 100 alive without the cancer growing at 48 months with Dara-VRd compared with VRd; 16.6 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 58 percent lower chance of the event at any given time (hazard ratio 0.42, likely range 0.3 to 0.59).
- 75.2 vs 47.5 out of 100 had no detectable disease on sensitive tests with Dara-VRd compared with VRd; 27.7 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed transplant-eligible myeloma: Dara-VRd induction/consolidation + DR maintenance vs VRd + R. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
709 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival at 48 monthsprimary | Dara-VRd | 355 | 84.3% | 0.42 (0.3–0.59) | <0.0001 | link |
| VRd | 354 | 67.7% | ||||
| MRD negativity (10⁻⁵) | Dara-VRd | — | 75.2% | — | — | — |
| VRd | — | 47.5% |
Pages like this
not linked directly; found by shared links- TrialCEPHEUS
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), Bortezomib, Daratumumab, Lenalidomide.
- PersonPaul G. Richardson
Shares Bortezomib, Lenalidomide, Autologous stem cell transplant (high-dose therapy), Multiple myeloma.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Daratumumab, Lenalidomide.
- TrialIMROZ
Shares CD38 antibody added to PI-IMiD-dex (quadruplet induction), Bortezomib, Lenalidomide, Multiple myeloma.
- Key paperCEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Bortezomib, Daratumumab, Lenalidomide.
- PersonKenneth C. Anderson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TermVRd and Dara-VRd (myeloma induction regimens)
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- TermMGUS and smouldering myeloma
Shares Daratumumab, Lenalidomide, Multiple myeloma.